Product news from the 10/10/06 News Brief
Merck said today that the FDA has approved oral Zolinza (vorinostat) for the treatment of cutaneous manifestations in patients with ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.